Emergent BioSolutions (NYSE:EBS) reported its Q2 earnings results on Monday, August 1, 2022 at 04:00 PM.
Here’s what investors need to know about the announcement.
Earnings
Emergent BioSolutions missed estimated earnings by 332.43%, reporting an EPS of $-0.86 versus an estimate of $0.37.
Revenue was down $154.80 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.06 which was followed by a 11.55% drop in the share price the next day.
Here’s a look at Emergent BioSolutions’s past performance:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | 0.12 | 4.27 | 2.35 | 1.54 |
| EPS Actual | 0.18 | 4.50 | -0.36 | 0.33 |
| Revenue Estimate | 283.00M | 691.36M | 486.84M | 398.93M |
| Revenue Actual | 307.50M | 723.20M | 329.00M | 397.50M |
To track all earnings releases for Emergent BioSolutions visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
